University of Maryland Division of Translational Radiation Sciences Selects Provantis Preclinical Software Solution
Provantis Selected to Automate and Optimize Study Processes at One of the World’s Largest Medical Countermeasure Programs
CONSHOHOCKEN, PA (BUSINESS WIRE) November 14, 2017 - Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that the University of Maryland School of Medicine, Baltimore, MD has purchased the Provantis® preclinical software solution to automate and optimize study processes at its Medical Countermeasure (MCM) Program, located within the Division of Translational Radiation Sciences.
The Division of Translational Radiation Sciences is dedicated to tackling the most important challenges in radiation-induced normal tissue injury, radiation cancer treatment and cancer survivorship.
The University of Maryland selected Provantis® to support an increasing research workload at their facility, enabling them to automate preclinical study processes and deliver increased efficiencies in the collection, storage and reporting of preclinical data. By harnessing Instem’s SaaS deployment model, the client will benefit from lower infrastructure and support costs, together with the flexibility and scalability to support further growth.
The Division of Translational Radiation Sciences was established to accelerate the discovery and clinical implementation of new therapeutic strategies to improve tumor response in clinical radiotherapy, minimize post-radiation therapy complications, and mitigate/treat the life-threatening health effects of a radioactive or nuclear agent. The division is home to one of the largest medical countermeasure programs in the world, conducting preclinical efficacy screens in the areas of acute radiation sickness (ARS) and delayed effects of acute radiation exposure (DEARE).
Isabel L. Jackson, PhD, assistant professor in the University of Maryland School of Medicine Department of Radiation Oncology and director of the Medical Countermeasure Program in the department’s Division of Translational Radiation Sciences said, “The implementation of Provantis will play a key role in enabling us to further expand our life-saving research, allowing us to automate and streamline processes and further improve data integrity, while maintaining Good Laboratory Practice (GLP) compliance.”
- Comprehensive suite of Provantis modules to be deployed including General Toxicology, Pathology, Clinical Pathology and Protocol & Report Assembly
- Provantis to replace existing manual processes and legacy software systems
- Client to harness the power of the Instem University e-learning platform, enabling users to quickly become proficient in Instem solutions
- University of Maryland has purchased a range of implementation services to ensure rapid deployment and quicker Return on Investment
- Client to access Provantis via the SaaS delivery model
Gregor Grant, Instem’s Executive Vice President of Preclinical Solutions said “The University of Maryland School of Medicine is widely recognized as a leader in the field of translational radiation science and we are honored that they have chosen Instem and Provantis to support them in their vital work. We warmly welcome them to the growing Provantis user community.”
About University of Maryland Division of Translational Sciences
Under the directorship of Zeljko Vujaskovic, MD, PhD, the Division of Translational Radiation Sciences (DTRS), within the Department of Radiation Oncology at the University of Maryland School of Medicine, is dedicated to tackling the most important challenges in radiation cancer treatment and cancer survivorship. The division was established to accelerate the discovery and clinical implementation of new therapeutic strategies to improve tumor response in clinical radiotherapy, minimize post-radiation therapy complications, and mitigate/treat the life-threatening health effects of a radioactive or nuclear agent. DTRS offers a multidisciplinary approach to address the knowledge gaps in radiation oncology, biology, and physics to facilitate discovery and innovation. This is accomplished through building on the experience and multidisciplinary expertise of faculty members within the Division. The Division provides a comprehensive set of services to the U.S. government, pharmaceutical, biotechnology, and medical device companies in the areas of medical and radiation oncology, radiation biology/physics and biodefense.
For further information please visit http://www.medschool.umaryland.edu/radonc/divisions/translational/
For further details about the Medical Countermeasure Program please visit http://www.medschool.umaryland.edu/radonc/divisions/translational/Medical-Countermeasure-Program/
Instem is a global provider of leading software solutions and services that are helping over 500 clients bring their life enhancing products to market faster. We enable clients in the life sciences to more efficiently collect, analyze, report and submit high quality regulatory data, while maintaining compliance for their products around the world.
Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making, leading to safer, more effective products.
Instem supports its global roster of clients through offices in the United States, United Kingdom, France, Japan, China and India.
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600
Gary Mitchell (US HQ)